

E J Crosbie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7316852/publications.pdf>

Version: 2024-02-01

123
papers

3,433
citations

147801

31
h-index

182427

51
g-index

126
all docs

126
docs citations

126
times ranked

3834
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. <i>Genetics in Medicine</i> , 2020, 22, 15-25.	2.4	365
2	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. <i>Genetics in Medicine</i> , 2019, 21, 2390-2400.	2.4	153
3	The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. <i>Genetics in Medicine</i> , 2019, 21, 2167-2180.	2.4	139
4	European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. <i>British Journal of Surgery</i> , 2021, 108, 484-498.	0.3	130
5	Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. <i>Human Reproduction Update</i> , 2014, 20, 853-868.	10.8	94
6	The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. <i>International Journal of Cancer</i> , 2019, 144, 641-650.	5.1	87
7	Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions. <i>Gynecologic Oncology</i> , 2016, 143, 287-293.	1.4	77
8	Measuring the biological effect of presurgical metformin treatment in endometrial cancer. <i>British Journal of Cancer</i> , 2016, 114, 281-289.	6.4	75
9	The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003295.	8.4	73
10	Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 491-495.	1.4	71
11	Identifying High-Risk Women for Endometrial Cancer Prevention Strategies: Proposal of an Endometrial Cancer Risk Prediction Model. <i>Cancer Prevention Research</i> , 2017, 10, 1-13.	1.5	68
12	The Management of Peutz-Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline. <i>Journal of Clinical Medicine</i> , 2021, 10, 473.	2.4	65
13	Obesity-driven endometrial cancer: is weight loss the answer?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 791-794.	2.3	59
14	Proteomic Biomarkers for the Detection of Endometrial Cancer. <i>Cancers</i> , 2019, 11, 1572.	3.7	59
15	The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. <i>PLoS Medicine</i> , 2020, 17, e1003263.	8.4	58
16	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017, 30, 459-468.	5.5	53
17	Prevention Strategies in Endometrial Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 101.	4.0	50
18	The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 150, 99-105.	1.4	49

#	ARTICLE	IF	CITATIONS
19	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1212-1220.	6.3	47
20	Top ten research priorities for detecting cancer early. <i>Lancet Public Health</i> , The, 2019, 4, e551.	10.0	45
21	Endometrial cancer prevention in high-risk women. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 66-78.	2.8	45
22	The surgical rectus sheath block for post-operative analgesia: a modern approach to an established technique. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 160, 196-200.	1.1	44
23	Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening. <i>BMJ Open</i> , 2019, 9, e025388.	1.9	43
24	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 8.	1.5	42
25	PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2424-2432.	7.0	41
26	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. <i>Cancers</i> , 2021, 13, 44.	3.7	40
27	Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer. <i>BMC Clinical Pathology</i> , 2017, 17, 27.	1.8	36
28	The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study. <i>Gynecologic Oncology</i> , 2018, 148, 154-160.	1.4	36
29	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. <i>Modern Pathology</i> , 2018, 31, 1851-1861.	5.5	35
30	Diagnostic accuracy of cytology for the detection of endometrial cancer in urine and vaginal samples. <i>Nature Communications</i> , 2021, 12, 952.	12.8	35
31	HE4 as a Biomarker for Endometrial Cancer. <i>Cancers</i> , 2021, 13, 4764.	3.7	35
32	The management of vulval cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 533-539.	7.7	34
33	Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer. <i>Metabolites</i> , 2020, 10, 314.	2.9	32
34	Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study. <i>Cancers</i> , 2020, 12, 1256.	3.7	32
35	Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. <i>Clinical Oncology</i> , 2021, 33, 550-559.	1.4	32
36	Epithelial ovarian cancer risk: A review of the current genetic landscape. <i>Clinical Genetics</i> , 2020, 97, 54-63.	2.0	31

#	ARTICLE	IF	CITATIONS
37	Association between genetic polymorphisms and endometrial cancer risk: a systematic review. <i>Journal of Medical Genetics</i> , 2020, 57, 591-600.	3.2	28
38	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. <i>Genetics in Medicine</i> , 2021, 23, 705-712.	2.4	28
39	Targeted lung cancer screening selects individuals at high risk of cardiovascular disease. <i>Lung Cancer</i> , 2018, 124, 148-153.	2.0	27
40	Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors. <i>Cancers</i> , 2019, 11, 653.	3.7	27
41	Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium. <i>Cancer Prevention Research</i> , 2021, 14, 1041-1050.	1.5	27
42	Developing role of HPV in cervical cancer prevention. <i>BMJ</i> , The, 2013, 347, f4781-f4781.	6.0	26
43	Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A Trans PORTEC initiative. <i>Gynecologic Oncology</i> , 2017, 146, 327-333.	1.4	26
44	Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD). <i>BMC Medical Genetics</i> , 2017, 18, 40.	2.1	25
45	Detecting endometrial cancer. <i>The Obstetrician and Gynaecologist</i> , 2021, 23, 103-112.	0.4	25
46	Prophylactic pre-operative bilateral ureteric catheters for major gynaecological surgery. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1061-1066.	1.7	24
47	Endometrial cancer and obesity. <i>The Obstetrician and Gynaecologist</i> , 2019, 21, 237-245.	0.4	23
48	Research priority setting in women's health: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 694-700.	2.3	23
49	Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. <i>PLoS ONE</i> , 2019, 14, e0221419.	2.5	22
50	Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin. <i>British Journal of Cancer</i> , 2020, 122, 62-71.	6.4	22
51	Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines. <i>BMC Cancer</i> , 2019, 19, 1028.	2.6	21
52	Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer cases. <i>Journal of Medical Genetics</i> , 2019, 56, 301-307.	3.2	21
53	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. <i>British Journal of Cancer</i> , 2015, 113, 786-793.	6.4	20
54	A cluster randomized trial of strategies to increase uptake amongst young women invited for their first cervical screen: The STRATEGIC trial. <i>Journal of Medical Screening</i> , 2018, 25, 88-98.	2.3	20

#	ARTICLE	IF	CITATIONS
55	The impact of obesity and bariatric surgery on the immune microenvironment of the endometrium. <i>International Journal of Obesity</i> , 2022, 46, 605-612.	3.4	20
56	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. <i>Histopathology</i> , 2019, 75, 813-824.	2.9	19
57	Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours. <i>BMC Cancer</i> , 2020, 20, 1000.	2.6	19
58	Biomarkers needed to predict progestin response in endometrial cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1584-1584.	2.3	18
59	Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer. <i>Cancers</i> , 2020, 12, 276.	3.7	18
60	Lynch syndrome for the gynaecologist. <i>The Obstetrician and Gynaecologist</i> , 2021, 23, 9-20.	0.4	18
61	Impact of socio-economic deprivation on endometrial cancer survival in the North West of England: a prospective database analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1215-1224.	2.3	18
62	The accuracy of the sentinel node procedure after excision biopsy in squamous cell carcinoma of the vulva. <i>Surgical Oncology</i> , 2010, 19, e150-e154.	1.6	17
63	Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer. <i>Cancers</i> , 2021, 13, 718.	3.7	17
64	Cost-Effectiveness of the Manchester Approach to Identifying Lynch Syndrome in Women with Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1664.	2.4	16
65	The prevalence of Lynch syndrome in women with endometrial cancer: a systematic review protocol. <i>Systematic Reviews</i> , 2018, 7, 121.	5.3	15
66	Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy. <i>Annals of Oncology</i> , 2019, 30, v899-v900.	1.2	15
67	Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. <i>Journal of Medical Genetics</i> , 2021, 58, 217-226.	3.2	15
68	Impact of surgical site infection (SSI) following gynaecological cancer surgery in the UK: a trainee-led multicentre audit and service evaluation. <i>BMJ Open</i> , 2019, 9, e024853.	1.9	14
69	The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population. <i>Cancers</i> , 2022, 14, 2124.	3.7	14
70	Obesity and endometrial cancer: unanswered epidemiological questions. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 175-178.	2.3	13
71	Assessment of mismatch repair deficiency in ovarian cancer. <i>Journal of Medical Genetics</i> , 2021, 58, 687-691.	3.2	13
72	Specialist oncological surgery for removal of the ovaries and fallopian tubes in <i>BRCA1</i> and <i>BRCA2</i> pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels. <i>International Journal of Cancer</i> , 2021, 148, 1155-1163.	5.1	13

#	ARTICLE	IF	CITATIONS
73	A mismatch in care: results of a United Kingdom-wide patient and clinician survey of gynaecological services for women with Lynch syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 728-736.	2.3	13
74	CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records. <i>British Journal of General Practice</i> , 2021, 71, e465-e472.	1.4	13
75	Cervical cancer: problem solved? Vaccinating girls against human papillomavirus. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2010, 117, 137-142.	2.3	12
76	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. <i>Journal of Clinical Medicine</i> , 2020, 9, 2290.	2.4	12
77	Identifying Ovarian Cancer in Symptomatic Women: A Systematic Review of Clinical Tools. <i>Cancers</i> , 2020, 12, 3686.	3.7	12
78	High prevalence of metabolic syndrome in women newly diagnosed with endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2018, 26, 109-110.	0.6	11
79	PROgesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study. <i>Cancer Prevention Research</i> , 2021, 14, 263-274.	1.5	11
80	Uptake and efficacy of bilateral risk reducing surgery in unaffected female <i>BRCA1</i> and <i>BRCA2</i> carriers. <i>Journal of Medical Genetics</i> , 2022, 59, 133-140.	3.2	11
81	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in <i>MLH1</i> and <i>MSH2</i> : A Prospective Lynch Syndrome Database Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2856.	2.4	11
82	<i>BRCA</i> and lynch syndrome-associated ovarian cancers behave differently. <i>Gynecologic Oncology Reports</i> , 2017, 22, 108-109.	0.6	11
83	Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. <i>Journal of Pathology</i> , 2022, 257, 340-351.	4.5	11
84	Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1842.	2.4	10
85	Comparison of two immunoassays for the measurement of serum HE4 for ovarian cancer. <i>Practical Laboratory Medicine</i> , 2021, 26, e00235.	1.3	10
86	The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3553-3559.	3.9	9
87	Comprehensive Library Generation for Identification and Quantification of Endometrial Cancer Protein Biomarkers in Cervico-Vaginal Fluid. <i>Cancers</i> , 2021, 13, 3804.	3.7	9
88	Re: Prediagnosis Body Mass Index, Physical Activity, and Mortality in Endometrial Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt375-djt375.	6.3	8
89	A Micro-Costing Study of Screening for Lynch Syndrome-Associated Pathogenic Variants in an Unselected Endometrial Cancer Population: Cheap as NGS Chips?. <i>Frontiers in Oncology</i> , 2019, 9, 61.	2.8	8
90	Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. <i>Cancers</i> , 2021, 13, 4538.	3.7	8

#	ARTICLE	IF	CITATIONS
91	The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2022, 151, 1626-1639.	5.1	8
92	Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer. <i>Cancers</i> , 2022, 14, 3306.	3.7	8
93	Does the vaginal microbiome drive cervical carcinogenesis?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 181-181.	2.3	7
94	Polygenic risk score opportunities for early detection and prevention strategies in endometrial cancer. <i>British Journal of Cancer</i> , 2020, 123, 1045-1046.	6.4	7
95	The Mirena coil is a suitable treatment of early-stage endometrial cancer in obese women. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1001-1001.	2.3	7
96	Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers. <i>Journal of Medical Genetics</i> , 2022, 59, 328-334.	3.2	7
97	Developing Tests for Endometrial Cancer deTECTION (DETECT): protocol for a diagnostic accuracy study of urine and vaginal samples for the detection of endometrial cancer by cytology in women with postmenopausal bleeding. <i>BMJ Open</i> , 2021, 11, e050755.	1.9	7
98	The vaginal microbiome and gynaecological cancer: exercise caution when considering causation. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 316-316.	2.3	6
99	Does Clinical and Biochemical Thyroid Dysfunction Impact on Endometrial Cancer Survival Outcomes? A Prospective Database Study. <i>Cancers</i> , 2021, 13, 5444.	3.7	6
100	Women's Risk Perceptions and Willingness to Engage in Risk-Reducing Interventions for the Prevention of Obesity-Related Endometrial Cancer. <i>International Journal of Women's Health</i> , 2022, Volume 14, 57-66.	2.6	6
101	Development and evaluation of polygenic risk scores for prediction of endometrial cancer risk in European women. <i>Genetics in Medicine</i> , 2022, 24, 1847-1856.	2.4	6
102	Urinary HPV testing may offer hope for cervical screening non-attenders. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1364-1364.	2.3	5
103	Apronectomy combined with laparotomy for morbidly obese endometrial cancer patients. <i>Surgical Oncology</i> , 2011, 20, e187-e193.	1.6	4
104	Authors' reply re: Mirena Coil is a suitable treatment of early-stage endometrial cancer in obese women: FOR or AGAINST?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1300-1301.	2.3	3
105	Synchronous uterine and bladder cancers detected in urine and vaginal samples by cytology. <i>Diagnostic Cytopathology</i> , 2022, 50, .	1.0	3
106	Uterine sarcoma: A rare cause of uterine inversion. <i>Journal of Obstetrics and Gynaecology</i> , 2009, 29, 776-778.	0.9	2
107	Soy intake and endometrial cancer risk varies according to study population. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2015, 122, 311-311.	2.3	2
108	Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants. <i>European Journal of Cancer</i> , 2020, 124, 88-90.	2.8	2

#	ARTICLE	IF	CITATIONS
109	BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?. British Journal of Cancer, 2022, 127, 163-167.	6.4	2
110	Gastrointestinal stromal tumour presenting as an ovarian tumour. Journal of Obstetrics and Gynaecology, 2010, 30, 324-325.	0.9	1
111	Global human papillomavirus vaccination: can it be cost-effective?. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 125-128.	2.3	1
112	Population-based testing of non-mucinous epithelial ovarian cancer in Scotland. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1459-1459.	2.3	1
113	Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial. , 2019, , .		1
114	Response to Benusiglio et al.. Genetics in Medicine, 2020, 22, 1424-1425.	2.4	1
115	Could Ovarian Cancer Prediction Models Improve the Triage of Symptomatic Women in Primary Care? A Modelling Study Using Routinely Collected Data. Cancers, 2021, 13, 2886.	3.7	1
116	Prevalence and prognosis of lynch syndrome and sporadic mismatch repair deficiency in the combined PORTEC-1,-2 and -3 endometrial cancer trials. , 2020, , .		1
117	Recent advances in the treatment of advanced or recurrent endometrial cancer. Expert Review of Obstetrics and Gynecology, 2009, 4, 521-532.	0.4	0
118	Commentary on "Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening". BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 40-47.	2.3	0
119	Are rigid management protocols stifling innovation in cancer treatment?. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 1432-1434.	2.3	0
120	Optimising fertility outcomes for women with early-stage cervical cancer: when less is more. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1736-1736.	2.3	0
121	Optimization of Window Study Endpoints in Endometrial Cancer. Frontiers in Oncology, 2019, 9, 428.	2.8	0
122	EPV284/#238...The early detection of vulvar cancer through self-examination (educate) study: what women and clinicians think. , 2021, , .		0
123	EPV128/#510...Womb cancer risk awareness: developing tools to influence change. , 2021, , .		0